The author's hypothesis is that adequate acetylcholine (ACh) hydrolysis inhibition acting through a physiological mechanism could maintain levels of the neurotransmitter sufficient to stimulate postsynaptic receptors which are still active in the brain of patiens affected by senile dementia of Alzheimer type (SDAT). We postulate that the use of reversible and specific cholinesterase inhibitors (ChEI) at optimal concentrations and with a suitable route of adminis tration would be more effective and less toxic than direct cholinergic stimulation by means of cholinomimetic agents. In order to formulate new strategies of treatment with ChEI we should take into consideration distinct differences of these drugs in their effects upon ACh levels in brain. In this review we will describe experimental approaches in animals and experimental treatment in humans which may help us to find optimal levels of ChE inhibition and ACh increases in brain. The effect of repeated doses of ChEI on serum and red blood cell (RBC) ChE activity are also discussed and correlated to the effect of acute and chronic administration on brain ACh. Severity of CNS symptoms seem to correlate more closely to percent of ACh increase in brain than to percent ChE inhibition at peak time or to time of recovery of ChE activity. These experi mental data on animals indicate that "slow release" drugs or intracerebral ad ministration of ChEI may be more effective in raising ACh levels in brain and, therefore, more suitable for therapy of Alzheimer patients.
Introduction
Cholinergic function is selectively and irreversibly affected in senile dementia of Alzheimer type (SDAT).1 Reduction of cholineacetyltransferase (ChAT) activity in the cortex of Alzheimer patients correlates with the degree of cognitive impairment as well as with the severity of the neuropathological terminal changes of Alzheimer dis ease.2,3 Thus, a direct relationship between loss of forebrain cholinergic cells and cortical cholinergic innervation, biochemical damage and symptoms of SDAT seems likely (Fig. 1 ). In addition, transient memory enhancement with the cholinesterase (ChE) inhibitor physostigmine (Phy) administered orally, s.c. or i.v. has been demon strated in Alzheimer patients (for review c.f. Giacobini, 1987) . 3 The mechanism in voked to explain such an improvement is the decreased hydrolysis of acetylcholine (ACh) following acetylcholinesterase (AChE) inhibition by Phy and the consequent increase in ACh levels in central cholinergic synapses, particularly in those that are related to memory circuits. We postulated that an adequate ACh hydrolysis inhibition acting through a physiological mechanism could maintain levels of neurotransmitter sufficient to stimulate postsynaptic receptors and that such mechanism would be more effective and less toxic than direct cholinergic stimulation by means of cholinomimetic agents.4 In order to formulate new strategies and effective modes of administration of cholinesterase inhibitors (ChEI) we should take into consideration the marked differ ences of these drugs in their effects on brain ACh. In this review we will discuss both new and classic experiments in animals and treatment in humans with ChE inhibitors which may help us to achieve maximal therapeutical effects at non-toxic levels of ChE inhibition and ACh increase in brain. Several AChEI have been tested chronically in order to produce ACh increases.
The administration of a constant low dose (0.3 mg/kg i.p.) of paraoxon to rats for 7 days does not produce symptoms until three days of treatment.12 Acetylcholine levels increase 50% during the first three days and remain fairly constant thereafter while ChE activity declines steadily during the four days of treatment to less than 20% of control activity. These results suggest that CNS symptoms are correlated with an in crease in total brain ACh and that a rise of 50% above control or higher, may trigger the appearance of more severe symptoms such as tremor and convulsions. A second point is that in acutely treated animals, total ACh levels may increase as much as 100% whereas in chronically treated animals total ACh values increased maximally by 50%.12
This suggests a change in the mechanisms regulating ACh synthesis or release. It is possible that the high ACh levels resulting from long-term ChE inhibition may compete for the re-uptake of Ch (Fig. 2) . It is generally accepted that a high percentage (70%)
E. Giacobini 384 Table 1 inhibition. This accumulation may inhibit acetylcholine synthesis as well as acetylcholine release. In addition, acetylcholinesterase inhibition might influence acetylcholine uptake as well as inhibit cholineacetyltransferase activity directly or in directly (through acetylcholine). of the Ch utilized for ACh synthesis is generated from ACh hydrolysis. Thus, a reduced availability of Ch due to lower ACh hydrolysis may contribute to reduce synthesis of ACh in chronically treated animals (Fig. 2) . Pretreatment with Ch prior to the ad ministration of a ChEI prevents Ch depletion in the striatum and potentiates ACh increase.12,15 However, this effect is not seen in hippocampus or cerebral cortex. Thus , regulatory mechanisms controlling synthesis of ACh appear to differ in various brain regions depending on the neuronal composition of a particular region (e.g. striatum vs. hippocampus). In addition, our recent studies show that different ChEI [Phy , metrifonate (MTF), tetrahydroaminoacridine (THA)] show markedly different effects on ACh release13 ( Table 2) . Severity of CNS symptoms seem to correlate closely to the percent of ACh increase in brain than to percent ChE inhibition at peak time or time of recovery of ChE activity (Table 2 ). Acute toxicity in animals is also different for different inhibitors ( Table 2 ). The effect of prolonged ChE inhibition has been extensively investigated both in animals and humans. In order to determine whether repeated doses of Phy resulted in increased tolerance, Koster16 injected various doses i.v. (0.25-2 mg/kg) at various intervals (45 min-100 hrs) repeated 2-4 times. In such experiments on 34 cats there was-no clear indication of a change in the sensitivity to Phy with regard to survival rate, severity of symptoms and rate of recovery from toxicity. Serum ChE activity was 20-33% inhibited after 0.1 mg/kg and 46% inhibited after 2 mg/kg at 30 minutes. Following DFP (0.1 mg/kg i.v.) serum ChE was 76-86% inhibited at 20 min, 71-84% at 4-6 hrs and was still -70% inhibited at 24 hrs. Other studies in animals relate more closely to various effects on the brain's cholinergic systems. It is interesting to note that when DFP was administered for longer periods at smaller dosages (0.5-1 mg/day for 50 days) symptoms were transient or absent in spite of the fact that RBC ChE activity was still 75% inhibited. It seems, therefore, that appearance and intensity of symptoms relate better to the activity level of ChE in the CNS or PNS rather than to peripheral ChE inhibition as measured by plasma and RBC levels of activity. These results in humans support our data in rats showing a close correlation between the activity of ChE in plasma and RBC and the curve of activity of ChE in brain after intramuscular injection of MTF and Phy suggesting that inhibition of ChE in plasma may be related to changes of this enzyme in brains The duration of symptoms in the CNS may also be related to the concentration of the inhibitor in that particular region. Our results in the rats demonstrated that following ChE inhibition by Phy, changes in levels of ACh can vary greatly from region to region (from 15% in medulla oblongata to 80% in cortex). We found in the rat a correlation between concentration of Phy and ChE inhibition (Fig. 3) in the CNS.6 This relation ship is independent of both dosage and route of administration. These results are important in determining therapeutical doses and monitoring effects of ChE in humans.4
Conclusion
A high degree of AChE inhibition with modestly elevated (10-15%) ACh levels can be maintained by using repeated doses of both reversible and irreversible ChEI. Since the risk for neuronal damage and the frequency and severity of toxic effects is higher with the irreversible agents it seems reasonable to consider for treatment purposes only reversible agents. However, various types of reversible AChEI (Phy, THA, MTF), show significant differences with regard to their effect on brain ACh, ACh release, toxicity and duration of action13 (Table 2) . Thus, control studies in animals should be helpful in suggesting the suitable agent, dosage and route of administration.6,13,21 Development of behavioral tolerance to ChEI does not seem to correlate to changes in 
